- Home
- VYNE vs ALLR Comparison
VYNE vs ALLR Comparison
Compare VYNE & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- ALLR
- Stock Information
- Founded
- VYNE 2003
- ALLR 2004
- Country
- VYNE United States
- ALLR United States
- Employees
- VYNE N/A
- ALLR N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- ALLR Health Care
- Exchange
- VYNE Nasdaq
- ALLR Nasdaq
- Market Cap
- VYNE 16.0M
- ALLR 15.8M
- IPO Year
- VYNE 2018
- ALLR N/A
- Fundamental
- Price
- VYNE $1.46
- ALLR $1.02
- Analyst Decision
- VYNE Strong Buy
- ALLR
- Analyst Count
- VYNE 2
- ALLR 0
- Target Price
- VYNE $6.25
- ALLR N/A
- AVG Volume (30 Days)
- VYNE 895.6K
- ALLR 440.9K
- Earning Date
- VYNE 08-13-2025
- ALLR 08-04-2025
- Dividend Yield
- VYNE N/A
- ALLR N/A
- EPS Growth
- VYNE N/A
- ALLR N/A
- EPS
- VYNE N/A
- ALLR N/A
- Revenue
- VYNE $605,000.00
- ALLR N/A
- Revenue This Year
- VYNE $42.51
- ALLR N/A
- Revenue Next Year
- VYNE N/A
- ALLR N/A
- P/E Ratio
- VYNE N/A
- ALLR N/A
- Revenue Growth
- VYNE 43.03
- ALLR N/A
- 52 Week Low
- VYNE $0.85
- ALLR $0.61
- 52 Week High
- VYNE $4.30
- ALLR $7.38
- Technical
- Relative Strength Index (RSI)
- VYNE 56.57
- ALLR 51.84
- Support Level
- VYNE $1.10
- ALLR $0.95
- Resistance Level
- VYNE $1.49
- ALLR $1.14
- Average True Range (ATR)
- VYNE 0.15
- ALLR 0.07
- MACD
- VYNE -0.00
- ALLR -0.00
- Stochastic Oscillator
- VYNE 90.45
- ALLR 38.46
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.